Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff

Silverback Therapeutics became the latest biotech to undertake a “strategic realignment” Thursday, revealing it would drop its two lead cancer programs — sending it back to the preclinical drawing board — and lay off more than a quarter of its staff.